Search Results
Search for other papers by Ruth Percik in
Google Scholar
PubMed
Search for other papers by Sherwin Criseno in
Google Scholar
PubMed
Search for other papers by Safwaan Adam in
Google Scholar
PubMed
Search for other papers by Kate Young in
Google Scholar
PubMed
Royal Marsden Hospital, London, UK
Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed
deficiency, whilst the inflammatory process itself may yield only minimal manifestations. As the hormone production of an involved gland ceases completely and irreversibly in most cases, lifelong hormone replacement should be initiated, whilst discontinuation
Search for other papers by Eleftherios E Deiktakis in
Google Scholar
PubMed
Search for other papers by Eleftheria Ieronymaki in
Google Scholar
PubMed
Search for other papers by Peter Zarén in
Google Scholar
PubMed
Search for other papers by Agnes Hagsund in
Google Scholar
PubMed
Search for other papers by Elin Wirestrand in
Google Scholar
PubMed
Search for other papers by Johan Malm in
Google Scholar
PubMed
Search for other papers by Christos Tsatsanis in
Google Scholar
PubMed
Imperial College London, Institute of Reproductive and Developmental Biology, London, UK
Search for other papers by Ilpo T Huhtaniemi in
Google Scholar
PubMed
Malmö University Hospital, Reproductive Medicine Center, Malmö, Sweden
Search for other papers by Aleksander Giwercman in
Google Scholar
PubMed
Search for other papers by Yvonne Lundberg Giwercman in
Google Scholar
PubMed
Introduction For decades, gonadotropin-releasing hormone (GnRH) agonists have formed the mainstay hormonal treatment of prostate cancer ( 1 ). While they generate suppression of testosterone due to persistent suppression of luteinizing hormone
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed
Search for other papers by Marilena Giannoudi in
Google Scholar
PubMed
Search for other papers by Satish S Kumar in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Khyatisha Seejore in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Harpal Randeva in
Google Scholar
PubMed
Leeds Institute of Medical Research, University of Leeds, UK
Search for other papers by Adam Glaser in
Google Scholar
PubMed
Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed
Search for other papers by Georgina Gerrard in
Google Scholar
PubMed
Search for other papers by Carmel Loughrey in
Google Scholar
PubMed
Search for other papers by Ahmed Al-Qaissi in
Google Scholar
PubMed
Search for other papers by Ramzi Ajjan in
Google Scholar
PubMed
Search for other papers by Julie Lynch in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Robert D Murray in
Google Scholar
PubMed
was during childhood in 16 and AO in 20. The mean radiotherapy dose to the tumour was 51.9 ± 10.1 Gy. Endocrine deficits were highly prevalent within the cohort (severe growth hormone deficiency (GHD) n = 22; partial GHD ( n = 10
Search for other papers by Judith Gebauer in
Google Scholar
PubMed
Search for other papers by Claire E Higham in
Google Scholar
PubMed
specialists. Topics will cover bone health, growth hormone deficiency, the impact of different radiotherapy techniques on the hypothalamic–pituitary axis, risk assessment for second cancers, as well as strategies for international collaboration and different
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Karhapää in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Siru Mäkelä in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Laurén in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Micaela Hernberg in
Google Scholar
PubMed
defined as a transition from suppressed TSH levels to increased levels, accompanied by corresponding changes of fT4 levels. Hypophysitis was defined as deficiencies in anterior pituitary hormones, that is ACTH, TSH, and gonadotropins, and their
Search for other papers by Sonja Kunz in
Google Scholar
PubMed
Search for other papers by Xiao Wang in
Google Scholar
PubMed
Search for other papers by Uta Ferrari in
Google Scholar
PubMed
Search for other papers by Michael Drey in
Google Scholar
PubMed
Search for other papers by Marily Theodoropoulou in
Google Scholar
PubMed
Search for other papers by Katharina Schilbach in
Google Scholar
PubMed
Search for other papers by Martin Reincke in
Google Scholar
PubMed
KORA Study Centre, University Hospital of Augsburg, Augsburg, Augsburg, Germany
Search for other papers by Margit Heier in
Google Scholar
PubMed
German Centre for Cardiovascular Research (DZHK), Partner site Munich Heart Alliance, Munich, Germany
Search for other papers by Annette Peters in
Google Scholar
PubMed
German Heart Centre Munich, Technical University of Munich, Munich, Germany
Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany
Search for other papers by Wolfgang Koenig in
Google Scholar
PubMed
German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany
Search for other papers by Tanja Zeller in
Google Scholar
PubMed
Search for other papers by Barbara Thorand in
Google Scholar
PubMed
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
N Arlt W & Krone N . Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Hormone Research in Paediatrics 2011 76 73 – 85 . ( https://doi.org/10.1159/000327794 ) 3 Eisenhofer G Masjkur J Peitzsch M Di
Search for other papers by Orwa Dandash in
Google Scholar
PubMed
Search for other papers by James Allebone in
Google Scholar
PubMed
Search for other papers by Adam Mirabelli in
Google Scholar
PubMed
Search for other papers by Nicholas Russell in
Google Scholar
PubMed
Search for other papers by Mathis Grossmann in
Google Scholar
PubMed
Department of Florey Institute, University of Melbourne, Parkville, Victoria, Australia
Search for other papers by Andrea Gogos in
Google Scholar
PubMed
Search for other papers by Richard A Kanaan in
Google Scholar
PubMed
Introduction Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone (GnRH) agonists is one of the mainstay therapies for prostate cancer ( 1 ). This therapy reduces circulating testosterone to castrate concentrations
Search for other papers by Anna Gorbacheva in
Google Scholar
PubMed
Search for other papers by Anna Eremkina in
Google Scholar
PubMed
Search for other papers by Daria Goliusova in
Google Scholar
PubMed
Search for other papers by Julia Krupinova in
Google Scholar
PubMed
Search for other papers by Natalia Mokrysheva in
Google Scholar
PubMed
cascades menin participates in ( 12 ). Menin in the development of bone disorders in MEN1 patients Parathyroid lesions in MEN1 manifest with PHPT, usually followed by hypersecretion of parathyroid hormone and hypercalcemia. Development of
Search for other papers by Matteo Scopel in
Google Scholar
PubMed
Search for other papers by Eugenio De Carlo in
Google Scholar
PubMed
Search for other papers by Francesca Bergamo in
Google Scholar
PubMed
Search for other papers by Sabina Murgioni in
Google Scholar
PubMed
Search for other papers by Riccardo Carandina in
Google Scholar
PubMed
Search for other papers by Anna Rita Cervino in
Google Scholar
PubMed
Search for other papers by Marta Burei in
Google Scholar
PubMed
Search for other papers by Federica Vianello in
Google Scholar
PubMed
Search for other papers by Vittorina Zagonel in
Google Scholar
PubMed
Search for other papers by Matteo Fassan in
Google Scholar
PubMed
Search for other papers by Roberto Vettor in
Google Scholar
PubMed
in both these groups the relationship between bone metastases, primary type/site of NET, laboratory parameters (chromogranin A (CgA), calcium, phosphate, parathyroid hormone (PTH) and vitamin D) and proliferation markers (Ki-67 and mitotic index